Server:Oscar Platform 20180...
The main IP address: 96.45.83.224,Your server United States,Reston ISP:Tiggee LLC TLD:com CountryCode:US
The description :
cancer & metabolism is proud to have leading experts who drive research in this niche field on its editorial board, reviewing manuscripts for quality, rather than focusing simply on nove...
This report updates in 25-Jun-2018
Created Date: | 2011-08-08 |
Changed Date: | 2017-08-02 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host cancerandmetabolism.com. Currently, hosted in United States and its service provider is Tiggee LLC .
Latitude: | 38.938861846924 |
Longitude: | -77.34619140625 |
Country: | United States (US) |
City: | Reston |
Region: | Virginia |
ISP: | Tiggee LLC |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called Oscar Platform 201802052158-170 containing the details of what the browser wants and will accept back from the web server.
Content-Length: | 19195 |
Expires: | 0 |
X-Forwarded-Host: | cancerandmetabolism.biomedcentral.com |
Etag: | "c14e00a530387a8257c747cb61b1166b" |
X-Cache-Hits: | 0 |
X-Frame-Options: | DENY |
X-Served-By: | cache-jfk8137-JFK |
X-B3-Traceid: | 5a80367e72a18a14 |
X-B3-Spanid: | f185a41b1d06592b |
Date: | Sun, 24 Jun 2018 17:45:05 GMT |
Age: | 0, 0 |
X-Sn-Servicetimems: | 96 |
X-Xss-Protection: | 1; mode=block |
X-Cache: | MISS |
Accept-Ranges: | bytes, bytes |
Strict-Transport-Security: | max-age=31536000;includeSubDomains;preload |
Content-Md5: | wU4ApTA4eoJXx0fLYbEWaw== |
Connection: | keep-alive |
Server: | Oscar Platform 201802052158-170 |
Via: | 1.1 varnish |
X-Content-Type-Options: | nosniff |
Content-Encoding: | gzip |
X-Timer: | S1529862305.985116,VS0,VE208 |
Vary: | Accept-Encoding,Accept,x-oscar-cache-mode,x-springer-property-json,X-Frame-Options |
X-Vcap-Request-Id: | 112dc673-ab1f-4a2e-507a-674b72f96190, bede12d5-fe9b-4f9a-6084-205f01e1b3cd |
Cache-Control: | private, must-revalidate |
Content-Type: | text/html; charset="UTF-8" |
soa: | ns10.dnsmadeeasy.com. dns.dnsmadeeasy.com. 2009010120 43200 3600 1209600 180 |
ns: | ns11.dnsmadeeasy.com. ns14.dnsmadeeasy.com. ns13.dnsmadeeasy.com. ns15.dnsmadeeasy.com. ns10.dnsmadeeasy.com. ns12.dnsmadeeasy.com. |
ipv4: | IP:96.45.83.224 ASN:16552 OWNER:TIGGEE - Tiggee LLC, US Country:US IP:96.45.82.248 ASN:16552 OWNER:TIGGEE - Tiggee LLC, US Country:US IP:96.45.83.39 ASN:16552 OWNER:TIGGEE - Tiggee LLC, US Country:US IP:96.45.82.109 ASN:16552 OWNER:TIGGEE - Tiggee LLC, US Country:US |
mx: | MX preference = 10, mail exchanger = mx2-class2-grp1.springernature.com. MX preference = 10, mail exchanger = mx1-class2-grp1.springernature.com. |
cancer & metabolism | home page skip to content advertisement menu explore journals get published about bmc login my account search search all bmc articles search cancer & metabolism menu home about articles submission guidelines search submit a manuscript articles recent most accessed content type: research | 11 june 2018 beta-hydroxybutyrate (3-ohb) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation authors: catharina bartmann, sudha r. janaki raman, jessica flöter, almut schulze, katrin bahlke, jana willingstorfer, maria strunz, achim wöckel, rainer j. klement, michaela kapp, cholpon s. djuzenova, christoph otto and ulrike kämmerer content type: research | 31 may 2018 isoform-specific deletion of pkm2 constrains tumor initiation in a mouse model of soft tissue sarcoma authors: talya l. dayton, vasilena gocheva, kathryn m. miller, arjun bhutkar, caroline a. lewis, roderick t. bronson, matthew g. vander heiden and tyler jacks content type: research | 17 april 2018 metabolic characterization of isocitrate dehydrogenase (idh) mutant and idh wildtype gliomaspheres uncovers cell type-specific vulnerabilities authors: matthew garrett, jantzen sperry, daniel braas, weihong yan, thuc m. le, jack mottahedeh, kirsten ludwig, ascia eskin, yue qin, rachelle levy, joshua j. breunig, frank pajonk, thomas g. graeber, caius g. radu, heather christofk, robert m. prins… content type: research | 3 april 2018 metabolomics of oncogene-specific metabolic reprogramming during breast cancer authors: chen dai, jennifer arceo, james arnold, arun sreekumar, norman j. dovichi, jun li and laurie e. littlepage content type: research | 3 april 2018 mutant idh1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner authors: pavithra viswanath, marina radoul, jose luis izquierdo-garcia, hema artee luchman, j. gregory cairncross, russell o. pieper, joanna j. phillips and sabrina m. ronen most recent articles rss view all articles content type: review | 7 march 2013 calorie restriction and cancer prevention: a mechanistic perspective authors: stephen d hursting, sarah m dunlap, nikki a ford, marcie j hursting and laura m lashinger content type: review | 24 july 2013 linking vitamin b1 with cancer cell metabolism authors: jason a zastre, rebecca l sweet, bradley s hanberry and star ye content type: review | 4 february 2014 hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways authors: norma masson and peter j ratcliffe content type: review | 25 january 2015 mitochondria as biosynthetic factories for cancer proliferation authors: christopher s ahn and christian m metallo content type: research | 6 september 2013 quinoline 3-sulfonamides inhibit lactate dehydrogenase a and reverse aerobic glycolysis in cancer cells authors: julia billiard, jennifer b dennison, jacques briand, roland s annan, deping chai, mariela colón, christopher s dodson, seth a gilbert, joel greshock, junping jing, hong lu, jeanelle e mcsurdy-freed, lisa a orband-miller, gordon b mills, chad j quinn, jessica l schneck… most accessed articles rss view all articles editors' profiles c hi van dang, editor emeritus chi dang is a professor, physician-researcher, renowned cancer biologist and hematologist-oncologist, who serves as director of the abramson cancer center at the university of pennsylvania. "after several decades of profound advances in our understanding of the genetics and molecular biology of cancer, it has become self-evident that metabolism and bioenergetics are regulated by cancer genes and are intimately linked to the growth and survival of cancer cells. the obesity pandemic connected to increased cancer risk further underscore the importance of a richer understanding of cancer and organismal metabolism. in this regard, cancer & metabolism is launched uniquely to fulfill the needs of a burgeoning field which is at the crossroads of many scientific disciplines." michael pollak, co-editor-in-chief michael pollak is an internationally recognized expert in cancer endocrinology at the lady davis institute for medical research of mcgill university and a clinical oncologist at the jewish general hospital, quebec, canada. " cancer & metabolism will provide a forum for rapid dissemination of research findings concerning metabolic factors that influence cancer risk and cancer pathophysiology, and cancer treatment. the scope of the journal will allow for an interdisciplinary readership including cancer biologists, endocrinologists, oncologists, clinical trialists and population scientists." supplements cancer & metabolism publishes selected collections of research articles, conference proceedings, reviews and reports as supplements. while we build our new sites all supplements will be available here . editors-in-chief michael pollak, mcgill university, canada matthew vander heiden, massachusetts institute of technology, usa senior editors kevin brindle, university of cambridge, uk navdeep chandel, northwestern university, usa ralph deberardinis, university of texas southwestern medical center, usa eyal gottlieb, beatson institute for cancer research, uk editor emeritus chi van dang, university of pennsylvania, usa aims and scope cancer & metabolism welcomes studies on all aspects of the relationship between cancer including molecular biology and genetics of cancer. read more efficient peer review we recognize that scientifically sound, high-quality manuscripts often receive negative decisions from high-impact journals on the basis of perceived general interest levels or the absence of extensive mechanisms supporting research hypotheses. as a niche journal, cancer & metabolism will consider rapid publication of such manuscripts if they are submitted together with the original peer reviewer reports, letter of rejection, and a brief rebuttal. featured article: mathematical models of cancer metabolism this review highlights the recent advances on the mathematical models of cancer metabolism. article collections cross journal article collection mitochondria guest edited by navdeep chandel (on behalf of cancer & metabolism), martin brand, andrew murray, jodi nunnari and peter walter, this cross journal collection focuses on all aspects of mitochondrial function in cancer and metabolism. read more advertisement submit a manuscript editorial board sign up for article alerts and news from this journal 2017 journal metrics speed 52 days from submission to first decision 13 days from acceptance to publication usage 110,995 downloads 1980.0 usage factor social media impact 21 mentions more about our metrics advertisement cancer & metabolism issn: 2049-3002 contact us submission enquiries: [email protected] general enquiries: [email protected] explore journals get published about bmc read more on our blogs receive bmc newsletters manage article alerts language editing for authors scientific editing for authors policies accessibility press center contact us leave feedback careers follow bmc bmc twitter page bmc facebook page bmc google plus page bmc weibo page by using this website, you agree to our terms and conditions , privacy statement and cookies policy. manage the cookies we use in the preference centre. © 2018 biomed central ltd unless otherwise stated. part of springer nature .
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/2049-3002-1-16
https://cancerandmetabolism.biomedcentral.com/articles/most-recent/rss.xml
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/2049-3002-1-10
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-018-0178-3
https://cancerandmetabolism.biomedcentral.com/about
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-015-0128-2
https://cancerandmetabolism.biomedcentral.com/about/editorial-board
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/s40170-018-0175-6
http://cancerandmetabolism.biomedcentral.com/about
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/2049-3002-1-19
https://cancerandmetabolism.biomedcentral.com/articles/10.1186/2049-3002-2-3
https://cancerandmetabolism.biomedcentral.com/articles/most-accessed/rss.xml
https://cancerandmetabolism.biomedcentral.com/#tab-2
https://cancerandmetabolism.biomedcentral.com/#tab-1
https://cancerandmetabolism.biomedcentral.com/articles
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain Name: CANCERANDMETABOLISM.COM
Registry Domain ID: 1670991489_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.eurodns.com
Registrar URL: http://www.EuroDNS.com
Updated Date: 2017-08-02T02:46:04Z
Creation Date: 2011-08-08T10:16:56Z
Registry Expiry Date: 2018-08-08T10:16:56Z
Registrar: EuroDNS S.A
Registrar IANA ID: 1052
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +352.27220150
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS10.DNSMADEEASY.COM
Name Server: NS11.DNSMADEEASY.COM
Name Server: NS12.DNSMADEEASY.COM
Name Server: NS13.DNSMADEEASY.COM
Name Server: NS14.DNSMADEEASY.COM
Name Server: NS15.DNSMADEEASY.COM
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-06-24T17:44:50Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
REGISTRAR EuroDNS S.A
SERVERS
SERVER com.whois-servers.net
ARGS domain =cancerandmetabolism.com
PORT 43
TYPE domain
DOMAIN
NAME cancerandmetabolism.com
CHANGED 2017-08-02
CREATED 2011-08-08
STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
NSERVER
NS10.DNSMADEEASY.COM 208.94.148.4
NS11.DNSMADEEASY.COM 208.80.124.4
NS12.DNSMADEEASY.COM 208.80.126.4
NS13.DNSMADEEASY.COM 208.80.125.4
NS14.DNSMADEEASY.COM 208.80.127.4
NS15.DNSMADEEASY.COM 208.94.149.4
REGISTERED yes
The following list shows you to spelling mistakes possible of the internet users for the website searched .